Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017
November 29 2017 - 9:30AM
Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of novel
therapeutic products that modulate the human gut microbiome to
treat gastrointestinal diseases, today announced that the Company’s
president, Andrew Ritter, will present at the 10th Annual LD Micro
Conference on Tuesday, December 5, 2017, at 9:00 a.m. PST in Los
Angeles.
Andrew Ritter will be available to participate
in one-on-one meetings with investors that week. Conference
participants who are interested in scheduling a meeting are
encouraged to sign up through the conference’s portal, or by
calling Shaun Novin at 310-203-1000.
The LD Micro Main Event is the largest
independent conference for small / microcap companies and will
feature over 200 of the most influential companies in the microcap
space. The conference will be held December 5-7, 2017, at the Luxe
Sunset Boulevard Hotel, located at: 11461 Sunset Boulevard, Los
Angeles.
The Company’s presentation will be available for
the public to access at www.ritterpharma.com. View Ritter
Pharmaceuticals profile here:
https://www.ldmicro.com/profile/RTTR.
About Ritter
Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops novel therapeutic
products that modulate the gut microbiome to treat gastrointestinal
diseases. Its lead product, RP‐G28, has the potential to become the
first FDA‐approved treatment for lactose intolerance, a condition
that affects millions worldwide. The Company is further exploring
the functionality and discovering the therapeutic potential gut
microbiome changes may have on treating/preventing a variety of
conditions including: gastrointestinal diseases, immuno‐oncology,
metabolic, and liver disease.
Forward-Looking Statements
This release may contain forward-looking
statements, which express the current beliefs and expectations of
Ritter Pharmaceuticals’ management. Such statements involve a
number of known and unknown risks and uncertainties that could
cause the Company’s future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Any
statements contained herein that do not describe historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those
discussed in such forward-looking statements. These forward-looking
statements are made only as of the date hereof, and the Company
undertakes no obligation to update or revise the forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
Investor Contact:
Jeffrey Benjamin
310-203-1000
Jeffrey@ritterpharma.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2023 to Apr 2024